Becton Dickinson (BDX) Raised to “Buy” at ValuEngine

ValuEngine upgraded shares of Becton Dickinson (NYSE:BDX) from a hold rating to a buy rating in a research report report published on Wednesday morning.

Other equities analysts also recently issued reports about the company. BMO Capital Markets assumed coverage on Becton Dickinson in a research note on Monday, March 5th. They issued a market perform rating and a $249.00 price objective for the company. Citigroup raised Becton Dickinson from a neutral rating to a buy rating and raised their price objective for the company from $237.00 to $251.00 in a research note on Tuesday, April 10th. Zacks Investment Research raised Becton Dickinson from a hold rating to a buy rating and set a $259.00 price objective for the company in a research note on Friday, January 19th. Bank of America reaffirmed a buy rating and issued a $260.00 price objective on shares of Becton Dickinson in a research note on Friday, January 19th. Finally, Morgan Stanley raised their price objective on Becton Dickinson from $245.00 to $250.00 and gave the company an equal weight rating in a research note on Wednesday, February 7th. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $241.19.

How to Become a New Pot Stock Millionaire

Shares of BDX stock opened at $232.88 on Wednesday. The company has a market cap of $62,630.89, a PE ratio of 24.57, a price-to-earnings-growth ratio of 1.71 and a beta of 1.15. Becton Dickinson has a 12-month low of $175.66 and a 12-month high of $248.39. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04.

Becton Dickinson (NYSE:BDX) last released its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating the consensus estimate of $2.41 by $0.07. Becton Dickinson had a return on equity of 16.19% and a net margin of 2.71%. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the business posted $2.33 EPS. Becton Dickinson’s quarterly revenue was up 5.4% on a year-over-year basis. equities research analysts expect that Becton Dickinson will post 10.95 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, March 30th. Shareholders of record on Friday, March 9th were issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.29%. The ex-dividend date of this dividend was Thursday, March 8th. Becton Dickinson’s dividend payout ratio (DPR) is presently 31.65%.

In other Becton Dickinson news, EVP Thomas E. Polen, Jr. sold 1,877 shares of the stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $227.00, for a total transaction of $426,079.00. Following the sale, the executive vice president now owns 15,387 shares in the company, valued at approximately $3,492,849. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the sale, the director now owns 295,753 shares in the company, valued at approximately $64,420,918.46. The disclosure for this sale can be found here. In the last quarter, insiders have sold 281,108 shares of company stock worth $61,321,396. 1.00% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in BDX. Legacy Advisors LLC grew its holdings in Becton Dickinson by 7,000.0% during the 4th quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after buying an additional 490 shares during the last quarter. Amica Retiree Medical Trust boosted its holdings in shares of Becton Dickinson by 325.0% during the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after purchasing an additional 390 shares during the last quarter. Almanack Investment Partners LLC. acquired a new stake in shares of Becton Dickinson during the fourth quarter worth $109,000. FTB Advisors Inc. boosted its holdings in shares of Becton Dickinson by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 290 shares during the last quarter. Finally, Advisors Preferred LLC acquired a new stake in shares of Becton Dickinson during the fourth quarter worth $126,000. Hedge funds and other institutional investors own 83.46% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Becton Dickinson (BDX) Raised to “Buy” at ValuEngine” was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://weekherald.com/2018/04/21/becton-dickinson-bdx-raised-to-buy-at-valuengine.html.

Becton Dickinson Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Becton Dickinson (NYSE:BDX)

Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply